Enveric Biosciences, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$8.8M | -$9.6M | -$16.4M | -$27.4M | -$64.6M |
| Cash from operations | -$8.1M | -$7.7M | -$14.1M | -$17.1M | -$11.5M |
| Capital expenditure | — | — | $5,180 | $584,165 | $189,719 |
| Free cash flow | — | — | -$14.1M | -$17.7M | -$11.6M |
| Impairments | — | — | — | $6.0M | $29.0M |
| Total assets | $5.1M | $3.1M | $4.3M | $19.6M | $26.7M |
| Total liabilities | — | — | — | $4.0M | $4.4M |
Shares outstanding 3.7M · Free float 98.8%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.